MKI67 and neoplasm: Furthermore, immunohistochemistry analysis on tumor samples revealed that SBI-46 severely compromised tumor viability, evidenced by lower expression of the proliferation markers Ki67, AR, AR-v7, and PSA in SBI-46-treated compared to the vehicle-treated mice.